Monocyte chemoattractant protein-1 (MCP-1/CCL2) and matrix metalloproteinase-9 (MMP-9) as biomarkers of disease severity in COVID-19 patients

单核细胞趋化蛋白-1 (MCP-1/CCL2) 和基质金属蛋白酶-9 (MMP-9) 作为 COVID-19 患者疾病严重程度的生物标志物

阅读:2

Abstract

BACKGROUND: Monocyte chemoattractant protein 1 (MCP1/CCL2) and matrix metalloproteinase (MMP9) in COVID-19 Patients are key immune elements that may be involved in COVID-19-induced cytokine storm. METHODS: We recruited patients in three patient groups, outpatient, hospitalized, and critical ICU COVID-19 cases as well as a group consisting of healthy controls. Venous blood was collected. Following the separation of peripheral blood mononuclear cells (PBMCs) which comprise various immune cells, total RNA extraction and cDNA generation were conducted. RT-PCR was achieved by primers exclusively designed for MMP9 and CCL2. RESULTS: For both MMP9 and CCL2 highest expression was found in PBMCs from critical COVID-19 cases. Interestingly, a J-shaped pattern of expression was found for both genes. CONCLUSION: MMP9 and CCL2 could be a potential clinical biomarker for patients with COVID-19. Regulation of these immune elements may be complex and responsible mechanisms deserve further investigation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。